کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1876494 | 1042018 | 2011 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
مهندسی و علوم پایه
فیزیک و نجوم
تشعشع
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies](/preview/png/1876494.png)
چکیده انگلیسی
Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin's Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. Monte Carlo simulation showed high doses deposited on a spheroid tumor mass model. This method seems to be an appropriate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Applied Radiation and Isotopes - Volume 69, Issue 7, July 2011, Pages 924–928
Journal: Applied Radiation and Isotopes - Volume 69, Issue 7, July 2011, Pages 924–928
نویسندگان
Paola F. Audicio, Gustavo Castellano, Marcos R. Tassano, Maria E. Rezzano, Marcelo Fernandez, Eloisa Riva, Ana Robles, Pablo Cabral, Henia Balter, Patricia Oliver,